We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy.
1. Please outline the current burden of head and neck cancer? (00:06)
2. Debio 1143 is currently under investigation for head and neck cancer, amongst several other cancers – please describe how this compound works? (00:44)
3. A Phase II trial of Debio 1143 in patients with head and neck cancer recently concluded, what were the key results and what is their potential impact? (01:21)
4. What are the next steps in the development of Debio 1143 for head and neck cancer? (01:55)
Jean Bourhis has participated in advisory boards for Merck, MSD, BMS and AstraZeneca.
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Head and Neck Cancer
Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and pembrolizumab + chemotherapy vs EXTREME in first-line recurrent/metastatic head and neck squamous cell carcinoma. Dr Makoto Tahara(Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss 5 years of follow-up in patients from KEYNOTE-048, and the […]
Jean-Pascal Machiels, ESMO 2022: Phase 3 KEYNOTE-412 study – efficacy and safety of pembrolizumab + chemoradiation therapy in locally advanced head and neck squamous cell carcinoma
Pembrolizumab is currently approved as monotherapy or in combination with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma. Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss the current limitations in treatment options, and the phase 3 KEYNOTE-412 study investigating the efficacy and safety of pembrolizumab + chemoradiation therapy (CRT) vs […]
Jean-Pascal Machiels, ESMO 2022: Highlights in head and neck cancer
Dr Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss clinical trial highlights in head and neck cancer presented at EMSO 2022. Questions: What are the hot topics and highlights in head and neck cancers from ESMO 2022? Disclosures: Jean-Pascal Machiels is an Advisory board member or speaker with honoraria (managed by my […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!